Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
December 3, 2020Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it will...Innate Pharma 2021 financial calendar
December 2, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial...Innate Pharma reports third quarter 2020 financial results and business update
November 17, 2020Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency Monalizumab Phase 3 study initiated, triggering $50 million milestone payment Cash position of €163.6 million*...Innate Pharma receives PRIME designation from the European Medicines Agency for lacutamab in Sézary syndrome
November 13, 2020Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Innate Pharma SA (Euronext Paris: IPH – ISIN:...Innate Pharma to participate in upcoming investor conferences
November 12, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that members of its senior management team are scheduled to participate in...Innate Pharma launches HopeConnectLearn: a new online resource for hairy cell leukemia patients
November 5, 2020New US website aims to educate and connect this rare disease community Rockville, Md., November 5, 2020, 8:00 AM EST Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("...
